Plasma osteopontin levels and adverse cardiovascular outcomes in the peace trial

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Abdalrhim, Ahmed D ^a   Marroush, Tariq S ^a   Austin, Erin E ^a   Gersh, Bernard J ^a   Solak, Nusret ^a   Rizvi, Syed A ^a   Bailey, Kent R ^a   Kullo, Iftikhar J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; PLACEBO; TRANDOLAPRIL; ANTIHYPERTENSIVE AGENT; INDOLE DERIVATIVE; SPP1 PROTEIN, HUMAN;

ADULT; ADVERSE CARDIOVASCULAR OUTCOME; AGE DISTRIBUTION; AGED; ARTICLE; BIOASSAY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; NON FATAL MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SANDWICH CHEMILUMINESCENT ASSAY; SEX DIFFERENCE; SMOKING; SURVIVAL RATE; SURVIVAL TIME; BLOOD; CARDIOVASCULAR SYSTEM; HEART STROKE VOLUME; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR SYSTEM; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS; RISK FACTORS; STROKE VOLUME;

EID: 84975745500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156965     Document Type: Article

References (27)

1. Ford ES, Giles WH, Croft JB. Prevalence of nonfatal coronary heart disease among American adults. Am Heart J. 2000; 139: 371-377. PMID: 10689247
2. Kassebaum NJ, Lopez AD, Murray CJ, Lozano R. A comparison of maternal mortality estimates from GBD 2013 and WHO. Lancet. 2014; 384: 2209-2210. doi: 10.1016/S0140-6736(14)62421-1 PMID: 25625393
3. Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, et al. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol. 2002; 161: 2035-2046. PMID: 12466120
4. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Sloan S, Jarolim P, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation. 2012; 125: 233-240. doi: 10.1161/CIRCULATIONAHA.111.063842 PMID: 22179538
5. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006; 16: 79-87. PMID: 16406521
6. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009; 3: 311-322. doi: 10.1007/s12079-009-0068-0 PMID: 19798593
7. Grau JB, Poggio P, Sainger R, Vernick WJ, Seefried WF, Branchetti E, et al. Analysis of osteopontin levels for the identification of asymptomatic patients with calcific aortic valve disease. Ann Thorac Surg. 2012; 93: 79-86. doi: 10.1016/j.athoracsur.2011.08.036 PMID: 22093695
8. Giachelli CM, Liaw L, Murry CE, Schwartz SM, Almeida M. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci. 1995; 760: 109-126. PMID: 7785890
9. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004; 35: 1636-1641. PMID: 15143295
10. Abdel-Azeez HA, Al-Zaky M. Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis. J Clin Lab Anal. 2010; 24: 201-206. doi: 10. 1002/jcla.20378 PMID: 20486203
11. Chen J, Lu Y, Huang D, Luo X, Zhang Y. Relationship of osteopontin and renal function with severity of coronary artery lesions. Int J Clin Exp Med. 2014; 7: 1122-1127. PMID: 24955193
12. Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, et al. Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis. 2003; 170: 333-337. PMID: 14612215
13. Wolak T. Osteopontin-a multi-modal marker and mediator in atherosclerotic vascular disease. Atherosclerosis. 2014; 236: 327-337. doi: 10.1016/j.atherosclerosis.2014.07.004 PMID: 25128758
14. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J. 2006; 27: 802-807. PMID: 16421174
15. Bjerre M, Pedersen SH, Mogelvang R, Lindberg S, Jensen JS, Galatius S, et al. High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention. Eur J Prev Cardiol. 2013; 20: 922-929. doi: 10.1177/2047487313487083 PMID: 23613225
16. Georgiadou P, Iliodromitis EK, Kolokathis F, Varounis C, Gizas V, Mavroidis M, et al. Osteopontin as a novel prognostic marker in stable ischaemic heart disease: a 3-year follow-up study. Eur J Clin Invest. 2010; 40: 288-293. doi: 10.1111/j.1365-2362.2010.02257.x PMID: 20192976
17. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al. Angiotensin-convertingenzyme inhibition in stable coronary artery disease. New Engl J Med. 2004; 351: 2058-2068. PMID: 15531767
18. R Core Team (2014) R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria.
19. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994; 81: 515-526.
20. Arnlov J, Evans JC, Benjamin EJ, Larson MG, Levy D, Sutherland P, et al. Clinical and echocardiographic correlates of plasma osteopontin in the community: the Framingham Heart Study. Heart. 2006; 92: 1514-1515. PMID: 16973806
21. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J. 1993; 7: 1475-1482. PMID: 8262332
22. Lorenzen JM, Neunhoffer H, David S, Kielstein JT, Haller H, Fliser D. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension-results from the EUTOPIA trial. Atherosclerosis. 2010; 209: 184-188. doi: 10.1016/j.atherosclerosis.2009.09.009 PMID: 19801149
23. Nunohiro T, Ashizawa N, Graf K, Do YS, Hsueh WA, Yano K. Angiotensin II promotes remodellingrelated events in cardiac fibroblasts. Heart Vessels. 1997; Suppl 12: : 201-204. PMID: 9476583
24. Zahradka P. Novel role for osteopontin in cardiac fibrosis. Circ Res. 2008; 102: 270-272. doi: 10.1161/ CIRCRESAHA.107.170555 PMID: 18276921
25. Soejima H, Irie A, Fukunaga T, Oe Y, Kojima S, Kaikita K, et al. Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ J. 2007; 71: 1879-1884. PMID: 18037740
26. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail. 2008; 1: 43-49. doi: 10.1161/ CIRCHEARTFAILURE.107.746172 PMID: 19808269
27. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW, et al. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension. 1999; 33: 663-670. PMID: 10024324